drugset / Trial / NCT07015801
CMV-specific Donor-derived T Lymphocytes for the Treatment of Recalcitrant CMV Infection in a Patient With Primary Immunodeficiency
Active not recruiting
1 enrolled
University of Calgary
Alberta Health services · collabAlberta Precision Laboratories · collabUniversity of Alberta · collab
NaSingle-groupOpen-labelTreatment
Summary
Treatment of CMV in a patient with profound combined immunodeficiency, who has viremia and pneumonia, using CMV-specific donor-derived T lymphocytes (CMV-VST).
Timeline
- Start
- 2025-04-15
- Primary completion
- 2027-04
- Completion
- 2040-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CMV-VST | Cell therapy | 30000 cells/kg | — |
| Subject | CMV-VST | Cell therapy | 40000 cells/kg | — |